Abstract
Purpose
Drug safety classifications give a very basic estimation of risk and should only be used as general guideline when assessing risk of pregnancy-related drug exposure or planning treatment. We conducted a study to assess the strength of association between both the clinical pharmacologists’ risk assessment and the FDA risk categorization, and adverse pregnancy outcomes.
Methods
We retrospectively reviewed records of 1,076 patients consecutively referred to the clinical pharmacology outpatient clinic for pregnancy-related drug exposure (2000–2008). Clinical pharmacologists’ risk assessments were reviewed in relation to FDA drug categorization and available pregnancy outcomes.
Results
Overall, clinical pharmacologists’ risk estimation was in agreement with the FDA risk categorization system in only 28% of consulted women, and in only 9% of women with high-risk exposure (FDA DX). Clinical pharmacologists’ risk assessment confirming high-risk drug exposure had a better positive predictive value for adverse pregnancy outcomes than the FDA DX categorization (25% vs 14% respectively), while the negative predictive values were similar (92% vs 94% respectively). Clinical pharmacologists’ risk assessment was a better predictor of adverse pregnancy outcomes compared with FDA risk categorization (OR 2.11 [95%CI 1.5-3.1; p < 0.001] vs OR 1.52 [95%CI 1.1-2.1; p = 0.014] respectively).
Conclusions
Additional evaluation beyond the FDA drug classification is essential for safer and more rational drug use in pregnancy. Clinical pharmacologists who have undergone rigorous medical training are ideally placed to consult on administration of medicines in pregnant women, thus making the prescribing of treatments in that patient category substantially safer and more rational.
Similar content being viewed by others
References
Oakley GP Jr (1986) Frequency of human congenital malformations. Clin Perinatol 13:545–554
Koren G (1994) Maternal-fetal toxicology: a clinician’s guide. Dekker, New York
Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL (2000) Prescription of drugs during pregnancy in France. Lancet 356:1735–1736. doi:10.1016/S0140-6736(00)03209-8
Haramburu F, Miremont G, Moride Y, Gomez MP, Douchet P, Douet C (1995) Drug prescription during pregnancy: a cohort study. Pharmacoepidemiol Drug Saf 4:74
Henry A, Crowther C (2000) Patterns of medication use during, and prior to pregnancy: the MAP study. Aus NZ J Obstet Gynaecol 40:165–172
Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W, Olatunbosun O, Wen SW (2008) Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 17(3):270–277. doi:10.1002/pds.1538
Webster WS, Freeman JA (2001) Is this drug safe in pregnancy? Reprod Toxicol 15(6):619–629. doi:10.1016/S0890-6238(01)00185-X
Boothby LA, Doering PL (2001) FDA labeling system for drugs in pregnancy. Ann Pharmacother 35(11):1485–1489
Addis A, Magrini N, Mastroiacovo P (2001) Drug use during pregnancy. Lancet 357:800. doi:10.1016/S0140-6736(05)71221-6
Addis A, Sharabi S, Bonati M (2000) Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 23(3):245–253
Feibus KB (2008) FDA’s proposed rule for pregnancy and lactation labelling: improving maternal child health through well-informed medicine use. J Med Toxicol 4(4):284–288
Bencarić L (2009) Registar Lijekova u Hrvatskoj. Udruga poslodavaca u zdravstvu, Zagreb
Vrhovac B et al (2007) Farmakoterapijski priručnik. Medicinska naklada, Zagreb
http://www.entis-org.com/en/aboutus.php. Accessed 2 June 2010
http://www.otispregnancy.org/goals-and-mission-s13030. Accessed 2 June 2010
ADEC: Australian Drug Evaluation Committee (1996) Medicines in Pregnancy—an Australian categorisation of risk of drug use in pregnancy. Australian Government Publishing Service, Canberra
Widnes F, Sofia K, Schjott J (2008) Advice on drug safety in pregnancy: are there differences between commonly used sources of information? Drug Saf 31(9):799–806
British Medical Association and Royal Pharmaceutical Society of Great Britain (2009) British National Formulary. BMJ Group and RPS Publishing, London
American Society of Health-System Pharmacists (2008) AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda
Briggs DD (2008) Drugs in pregnancy and lactation. Lippincot Williams Wilkins, Philadelphia
Micromedex® Healthcare Series Vol. 144, expires 6/2010
www.ncbi.nlm.nih.gov/pubmed/. Accessed 2 June 2010
Sannerstedt R, Lundborg P, Danielsson BR, Kihlstrom I, Alvan G, Prame B, Ridley E (1996) Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 14:69–77
Buhimschi CS, Weiner CP (2009) Medications in pregnancy and lactation. I. Teratology. Obstet Gynecol 113(1):166–188
Lee E, Maneno MK, Smith L, Wiess SR, Zuckerman IH, Wutoh AK, Xue Z (2006) National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 15(8):537–545. doi:10.1002/pds.1241
Culig J, Leppee M, Stimac D, Kuvacic I, Pulanic-Klepac T, Herman R, Tuckar N, Podobnik M, Klobucar A, Matesa S, Polic-Vizintin M, Damic A (2007) Cross-sectional study of drug use in pregnancy. Lijec Vjesn 129:253–259
Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH, Yood MU, Platt R, Gurwitz JH (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15(8):546–554. doi:10.1002/pds.1235
http://www.dzs.hr/Hrv_Eng/menandwomen/men_and_women_2009.pdf. Accessed 2 June 2010
Adams P, Hendershot G, Marano M (1999) Current estimates from the National Health Interview Survey. Vital Health Stat 10:83–84
Kovacić L, Gazdek D, Samardzić S (2007) Croatian health survey: cigarette smoking. Acta Med Croat 61(3):281–285
http://www.hzjz.hr/publikacije/porodi2008.pdf. Accessed 2 June 2010
Briggs GG, Freeman RK, Yaffe JS (2008) Drugs in pregnancy and lactation. Lippincott Williams & Willkins, Philadelphia
http://www.eurocat-network.eu/prevdata/results.aspx?title=A1&allanom=false&allregf=true&allrega=falseundefined&winx=1256&winy=894. Accessed 2 June 2010
Nybo Andersen AM, Wohlfart J, Christens P, Olsen J, Melbye M (2000) Maternal age and fetal loss: population based register linkage study. BMJ 320:1708–1712
De La Rochebrochard E, Thonneau P (2002) Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum Reprod 17(6):1649–1656
http://www.hzjz.hr/publikacije/prekidi_2008.pdf. Accessed 2 June 2010
Delbaere I, Verstraelen H, Goetgeluk S, Martens G, De Backer G, Temmerman M (2007) Pregnancy outcome in primiparae of advanced maternal age. Eur J Obstet Gynecol Reprod Biol 135(1):41–46. doi:10.1016/j.ejogrb.2006.10.030
Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ (2006) Pregnancy outcomes in women with congenital heart disease. Circulation 113:517–524. doi:10.1161/CIRCULATIONAHA.105.589655
Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81(1):1–13. doi:10.1016/j.eplepsyres.2008.04.022
Bai J, Wong FWS, Bauman A, Mohsin M (2002) Parity and pregnancy outcomes. Am J Obstet Gynecol 186(2):274–278. doi:10.1067/mob.2002.119639
Engeland A, Bramness JG, Dalveit AK, Ronning M, Skurtveit S, Furu K (2008) Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 65(5):653–660. doi:10.1111/j.1365-2125.2008.03102.x
http://www.socialstyrelsen.se/register/halsodataregister/medicinskafodelseregistret/inenglish. Accessed 2 June 2010
Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38:981–990
Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C (2002) Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99:35–40
Acknowledgements
This study did not receive any external funding. We acknowledge the help of our nurses Ana Anđelić and Marijana Križic-Erceg.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erdeljić, V., Francetić, I., Makar-Aušperger, K. et al. Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy?. Eur J Clin Pharmacol 66, 1037–1046 (2010). https://doi.org/10.1007/s00228-010-0867-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0867-5